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Dear Editor,
There is a concern of the presence of asymptomatic patients with
coronavirus infection such as the Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) [1]. The emergence of the SARS-CoV-2
(COVID-19) in Wuhan city, China had raised international concerns
about the potential occurrence of a pandemic. Understanding the viral
loads of SARS-CoV-2 is an important aspect to enhance the knowledge
of the disease and understanding of the transmission mechanism. In a
recent paper, Zou et al. described SARS-CoV-2 viral load in upper re-
spiratory samples of infected patients [2]. These patients had peak viral
loads about 3 days after onset of symptoms with a higher load in the
nose than the throat, thus mimicking influenza [2]. In the SARS pa-
tients, viral loads peak occurred 10 days after symptom onset [3]. Those
patients had higher viral loads later in the course of the disease in lower
respiratory samples. Similarly, in the case of the Middle East Re-
spiratory Syndrome Coronavirus (MERS-CoV), viral load peaked about
the second day of hospitalization in the upper respiratory samples and
about the sixth day in the lower respiratory samples [4]. These findings
parallel the findings from SARS-CoV [3]. In addition, the peak upper
respiratory tract RNA occurred on day 7–10 after onset in community
cases [5].
There was a higher percentage of positive upper respiratory tract
samples in MERS-CoV (47.6%) compared to the 38% in SARS-CoV [5].
However, these studies are not comparable as the reference point was
either onset of symptoms for SARS or admission for MERS-CoV. Further
studies showed that MERS-CoV RNA levels peaked during the first week
after onset in the upper respiratory tract samples of patients who did
not require supplemental oxygen compared to a peak viral load in the
2nd and 3rd week in those who required oxygen depending on lower
respiratory tract samples [6].
Another difference is that in MERS-CoV, the viral RNA was detected
in the nasopharyngeal-swab of 29% and in the throat-swab of 59% of
patients [7] and this is in sharp contrast with the SARS-CoV-2 [2].
There was persistent viral load beyond 3 weeks in severe cases of MERS
and SARS [7]. There is a need to study viral dynamics of SARS-CoV-2 in
mild and severe cases and study the duration of shedding to further
enhance our understanding of SARS-CoV-2. These studies will aid in the
development of infection control and public health measures in order to
decrease the transmission of the virus. In addition, such studies will
further enhance our understanding of the severity of cases and possible
contributing factors to severity of SARS-CoV-2.
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